# Study of BLZ-100 in Pediatric Subjects With CNS Tumors

> **NCT02462629** · PHASE1 · COMPLETED · sponsor: **Blaze Bioscience Inc.** · enrollment: 29 (actual)

## Conditions studied

- Central Nervous System Tumors

## Interventions

- **DRUG:** BLZ-100

## Key facts

- **NCT ID:** NCT02462629
- **Lead sponsor:** Blaze Bioscience Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-06
- **Primary completion:** 2018-07
- **Final completion:** 2018-08
- **Target enrollment:** 29 (ACTUAL)
- **Last updated:** 2023-02-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02462629

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02462629, "Study of BLZ-100 in Pediatric Subjects With CNS Tumors". Retrieved via AI Analytics 2026-06-30 from https://api.ai-analytics.org/clinical/NCT02462629. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*